Document Detail

Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors.
MedLine Citation:
PMID:  11228548     Owner:  NLM     Status:  MEDLINE    
Arsenic trioxide, As2O3 (ATO), has been found to be an effective chemotherapeutic for acute promyelocytic leukemia but its effect on solid tumors has not been fully explored. In the present report, we describe our observation that ATO is a potent antivascular agent and that it markedly enhances the effect of hyperthermia on tumors. The tumor blood perfusion in SCK tumors of A/J mice and FSaII tumors of C3H mice was significantly suppressed for up to 24 hours after an i.p. injection of 8 mg/kg ATO. ATO was also found to be able to increase the thermosensitivity of tumor cells in vitro. As a probable consequence of these effects, ATO treatment markedly increased the tumor growth delay caused by hyperthermia at 41.5 to 42.5 degrees C. Immunohistochemical staining of tumor tissue revealed that the expression levels of several adhesion molecules and TNFalpha are noticeably increased in tumors 2 to 6 hours after systemic ATO treatment. It is concluded that ATO is potentially useful to enhance the effect of hyperthermia on tumors at a clinically relevant temperature.
R J Griffin; S H Lee; K L Rood; M J Stewart; J C Lyons; Y S Lew; H Park; C W Song
Related Documents :
2773188 - A new method of investigating the efficacy of regional thermotherapy in subcutaneous xe...
3768758 - The influence of levamisole and hyperthermia on the incidence of metastases from an x-i...
20091868 - Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and...
3123758 - Effect of oxygen tension on the antitumor activity of mitomycin c assayed by human tumo...
19581738 - Syndecan-1 and tenascin expression in cystic tumors of the pancreas.
22998528 - Chemistry and pharmacology of imexon and related cyanoaziridines.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Neoplasia (New York, N.Y.)     Volume:  2     ISSN:  1522-8002     ISO Abbreviation:  Neoplasia     Publication Date:    2000 Nov-Dec
Date Detail:
Created Date:  2001-03-06     Completed Date:  2002-04-01     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  100886622     Medline TA:  Neoplasia     Country:  United States    
Other Details:
Languages:  eng     Pagination:  555-60     Citation Subset:  IM    
Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Antineoplastic Agents / therapeutic use*
Arsenicals / therapeutic use*
E-Selectin / metabolism
Fibrosarcoma / blood supply*,  pathology,  therapy
Hyperthermia, Induced*
Intercellular Adhesion Molecule-1 / metabolism
Mammary Neoplasms, Experimental / blood supply*,  pathology,  therapy
Mice, Inbred A
Mice, Inbred C3H
Neovascularization, Pathologic / drug therapy*,  metabolism
Oxides / therapeutic use*
Tumor Cells, Cultured
Tumor Necrosis Factor-alpha / metabolism
Vascular Cell Adhesion Molecule-1 / metabolism
Grant Support
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents; 0/Arsenicals; 0/E-Selectin; 0/Oxides; 0/Tumor Necrosis Factor-alpha; 0/Vascular Cell Adhesion Molecule-1; 126547-89-5/Intercellular Adhesion Molecule-1; 1327-53-3/arsenic trioxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The relationship between spontaneous telomere loss and chromosome instability in a human tumor cell ...
Next Document:  Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tum...